Katkin Keith — SEC Form 4 filings
SEC reporting owner CIK 1314596. 10 Form 4 filings on record with FilingPulse; latest filed 2026-05-04.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-02-09 to 2026-05-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 10,000 shares, $91,120 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 23,325 shares, $177,600 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: sale of 15,481 shares @ $8.28 ($128,183) in Emergent BioSolutions Inc., filed 2026-05-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | Director | 4 | — | 2 legs · 23,325 sh · $177,600 | 6 |
| Syndax Pharmaceuticals Inc (SNDX) | Director | 4 | 1 leg · 10,000 sh · $91,120 | — | 3 |
| Eledon Pharmaceuticals, Inc. (ELDN) | Director | 2 | — | — | 4 |
Form 4 filings — Katkin Keith
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-04 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 25,344 @ $0 · Sale (S): 15,481 @ $8.28 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2026-01-16 | 4 | Eledon Pharmaceuticals, Inc. (ELDN) | Option exercise (M): 8,575 @ $0 · Option exercise (M): 8,575 (derivative) @ $0 | EDGAR |
| 2025-05-28 | 4 | Emergent BioSolutions Inc. (EBS) | Sale (S): 7,844 @ $6.30 | EDGAR |
| 2025-05-19 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Purchase (P): 10,000 @ $9.11 | EDGAR |
| 2025-05-02 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 34,403 @ $0 · Grant/award (A): 15,824 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-01-13 | 4 | Eledon Pharmaceuticals, Inc. (ELDN) | Grant/award (A): 77,175 (derivative) @ $0 · Grant/award (A): 8,575 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 17,430 @ $0 · Grant/award (A): 25,748 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 17,000 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1314596 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →